Visceral Leishmaniasis Treatment, Europe

Gradoni, Luigi; Gramiccia, Marina; Scalone, Aldo

doi:10.3201/eid0912.030178

i

Visceral Leishmaniasis Treatment, Europe

Supporting Files Public Domain

Dec 2003
By Gradoni, Luigi ; Gramiccia, Marina ; Scalone, Aldo

Details

Alternative Title:

Emerg Infect Dis
Personal Author:

Gradoni, Luigi ; Gramiccia, Marina ; Scalone, Aldo
Description:

First-line drug treatment was recorded in 573 immunocompetent patients with visceral leishmaniasis in Europe. In the past 12 years, the proportion of antimonial treatments decreased from 100% to 2.8%, while the proportion of amphotericin B treatments increased from 0% to 97.2%. The countrywide change in therapy is a response to both disease reemergence and increasing antimonial failure.
Subjects:

Adolescent Adult Amphotericin B Animals Antiprotozoal Agents Child Dispatch Drug Combinations Drug Therapy Drug Treatment Europe Humans Leishmania Infantum Leishmaniasis, Visceral Meglumine Organometallic Compounds Pentavalent Antimony Phosphatidylcholines Phosphatidylglycerols Retrospective Studies Visceral Leishmaniasis
Source:

Emerg Infect Dis. 9(12):1617-1620.
Document Type:

Journal Article
Volume:

9
Issue:

12
Collection(s):

Emerging Infectious Diseases
Main Document Checksum:

urn:sha256:baa3727dbad7356bbf41ee522c267b51b4de2e7dbce2db1a86156f8898b2f0e0
Download URL:

https://stacks.cdc.gov/view/cdc/14285/cdc_14285_DS1.pdf
File Type:

[PDF - 325.99 KB ]

ON THIS PAGE

Details Supporting Files

CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners.

As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.